首页> 外文期刊>International Journal of Pharmacology >Comparing Efficacy and Safety of Olopatadine and Emedastine in Patients with Allergic Conjunctivitis
【24h】

Comparing Efficacy and Safety of Olopatadine and Emedastine in Patients with Allergic Conjunctivitis

机译:盐酸奥洛他定和艾美达汀治疗过敏性结膜炎的疗效和安全性比较

获取原文
           

摘要

Background and Objective: Anti-histamine and anti-inflammatory agents are used in treatment of allergic conjunctivitis. The objective of the study was to compare efficacy and safety of emedastine with olopatadine in Chinese allergic conjunctivitis patients. Materials and Methods: Total, 2,745 allergic conjunctivitis affected eyes were subjected to simple randomization. Patients received normal saline (VG group; n = 915), 0.2% olopatadine (OG group; n = 915) or emedastine (EG group; n = 915) in affected eyes. Interventions run for 15 days. The signs, symptoms and treatment-emergent adverse-effects were evaluated. Results: Olopatadine and emedastine were effective and safe in allergic conjunctivitis. In the morning, patients had the same satisfaction for the relief of symptoms for olopatadine and emedastine (4.32±0.25 vs. 4.29±0.38, p = 0.051). In the evening, patients had a higher satisfaction for the relief of symptoms for emedastine treatment than olopatadine treatment (4.12±0.11 vs. 2.14±0.11, pConclusion: Olopatadine recommended in all types of conjunctivitis and emedastine recommended in seasonal and perennial allergic conjunctivitis only.
机译:背景与目的:抗组胺药和抗炎药被用于治疗过敏性结膜炎。这项研究的目的是比较依美司汀和奥洛他定在中国过敏性结膜炎患者中的疗效和安全性。材料与方法:对总计2,745例受变应性结膜炎影响的眼睛进行简单随机分组。患者在患眼中接受了生理盐水(VG组; n = 915),0.2%的奥洛他定(OG组; n = 915)或艾美他汀(EG组; n = 915)。干预进行了15天。评价了症状,症状和出现的治疗不良反应。结果:奥洛他定和艾美他汀在过敏性结膜炎中安全有效。早晨,患者对奥洛他定和依美司汀的症状缓解具有相同的满意度(4.32±0.25 vs. 4.29±0.38,p = 0.051)。到了晚上,患者对缓解氨丁斯汀的症状的满意度比奥洛帕定治疗的满意度更高(4.12±0.11 vs.2.14±0.11,p)结论:在所有类型的结膜炎中推荐使用奥洛他定,仅在季节性和常年性变应性结膜炎中推荐使用依美他汀。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号